534 related articles for article (PubMed ID: 30549039)
1. The genomic alterations of lung adenocarcinoma and lung squamous cell carcinoma can explain the differences of their overall survival rates.
Meng F; Zhang L; Ren Y; Ma Q
J Cell Physiol; 2019 Jul; 234(7):10918-10925. PubMed ID: 30549039
[TBL] [Abstract][Full Text] [Related]
2. Exploring and comparing of the gene expression and methylation differences between lung adenocarcinoma and squamous cell carcinoma.
Yang Y; Wang M; Liu B
J Cell Physiol; 2019 Apr; 234(4):4454-4459. PubMed ID: 30317601
[TBL] [Abstract][Full Text] [Related]
3. Elevated PHD2 expression might serve as a valuable biomarker of poor prognosis in lung adenocarcinoma, but no lung squamous cell carcinoma.
Xu XL; Gong Y; Zhao DP
Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8731-8739. PubMed ID: 30575913
[TBL] [Abstract][Full Text] [Related]
4. Differential
Lin S; Tian C; Li J; Liu B; Ma T; Chen K; Gong W; Wang JM; Huang J
Oncol Rep; 2021 May; 45(5):. PubMed ID: 33786615
[TBL] [Abstract][Full Text] [Related]
5. GPC3 affects the prognosis of lung adenocarcinoma and lung squamous cell carcinoma.
Ning J; Jiang S; Li X; Wang Y; Deng X; Zhang Z; He L; Wang D; Jiang Y
BMC Pulm Med; 2021 Jun; 21(1):199. PubMed ID: 34112123
[TBL] [Abstract][Full Text] [Related]
6. Prognostic alternative mRNA splicing signature in non-small cell lung cancer.
Li Y; Sun N; Lu Z; Sun S; Huang J; Chen Z; He J
Cancer Lett; 2017 May; 393():40-51. PubMed ID: 28223168
[TBL] [Abstract][Full Text] [Related]
7. LncRNAs are altered in lung squamous cell carcinoma and lung adenocarcinoma.
Liu B; Chen Y; Yang J
Oncotarget; 2017 Apr; 8(15):24275-24291. PubMed ID: 27903974
[TBL] [Abstract][Full Text] [Related]
8. System analysis of
Situ Y; Gao R; Lei L; Deng L; Xu Q; Shao Z
Int J Biol Markers; 2022 Jun; 37(2):158-169. PubMed ID: 35254116
[TBL] [Abstract][Full Text] [Related]
9. Comparative study on the mutational profile of adenocarcinoma and squamous cell carcinoma predominant histologic subtypes in Chinese non-small cell lung cancer patients.
Ding Y; Zhang L; Guo L; Wu C; Zhou J; Zhou Y; Ma J; Li X; Ji P; Wang M; Zhu W; Shi C; Li S; Wu W; Zhu W; Xiao D; Fu C; He Q; Sun R; Mao X; Lizaso A; Li B; Han-Zhang H; Zhang Z
Thorac Cancer; 2020 Jan; 11(1):103-112. PubMed ID: 31692283
[TBL] [Abstract][Full Text] [Related]
10. The value of CEP55 gene as a diagnostic biomarker and independent prognostic factor in LUAD and LUSC.
Fu L; Wang H; Wei D; Wang B; Zhang C; Zhu T; Ma Z; Li Z; Wu Y; Yu G
PLoS One; 2020; 15(5):e0233283. PubMed ID: 32437446
[TBL] [Abstract][Full Text] [Related]
11. Identification of Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Wang J; Zhan X
Front Immunol; 2021; 12():752643. PubMed ID: 34887858
[TBL] [Abstract][Full Text] [Related]
12. LDHA upregulation independently predicts poor survival in lung adenocarcinoma, but not in lung squamous cell carcinoma.
Yu C; Hou L; Cui H; Zhang L; Tan X; Leng X; Li Y
Future Oncol; 2018 Oct; 14(24):2483-2492. PubMed ID: 29756998
[TBL] [Abstract][Full Text] [Related]
13. Prediction of Responsiveness to PD-L1/PD-1 Inhibitors Using miRNA Profiles Associated With PD-L1 Expression in Lung Adenocarcinoma and Squamous Cell Carcinoma.
Koh YW; Han JH; Haam S; Lee HW
Anticancer Res; 2024 May; 44(5):2081-2089. PubMed ID: 38677736
[TBL] [Abstract][Full Text] [Related]
14. A prognosis-related molecular subtype for early-stage non-small lung cell carcinoma by multi-omics integration analysis.
Yang K; Wu Y
BMC Cancer; 2021 Feb; 21(1):128. PubMed ID: 33549049
[TBL] [Abstract][Full Text] [Related]
15.
Zhang W; Li T; Hu B; Li H
Technol Cancer Res Treat; 2020; 19():1533033820957030. PubMed ID: 33084541
[TBL] [Abstract][Full Text] [Related]
16. Cancer Stemness-Based Prognostic Immune-Related Gene Signatures in Lung Adenocarcinoma and Lung Squamous Cell Carcinoma.
Li N; Li Y; Zheng P; Zhan X
Front Endocrinol (Lausanne); 2021; 12():755805. PubMed ID: 34745015
[TBL] [Abstract][Full Text] [Related]
17. Downregulation of HOXA3 in lung adenocarcinoma and its relevant molecular mechanism analysed by RT-qPCR, TCGA and in silico analysis.
Gan BL; He RQ; Zhang Y; Wei DM; Hu XH; Chen G
Int J Oncol; 2018 Oct; 53(4):1557-1579. PubMed ID: 30066858
[TBL] [Abstract][Full Text] [Related]
18. Insights into the heterogeneity of the tumor microenvironment in lung adenocarcinoma and squamous carcinoma through single-cell transcriptomic analysis: Implications for distinct immunotherapy outcomes.
Fang X; Li D; Wan S; Hu J; Zhang P; Jie D; Chen L; Jiang G; Song N
J Gene Med; 2024 Jun; 26(6):e3694. PubMed ID: 38847309
[TBL] [Abstract][Full Text] [Related]
19. High
Xie L; Dang Y; Guo J; Sun X; Xie T; Zhang L; Yan Z; Amin H; Guo X
Genes (Basel); 2019 Jan; 10(1):. PubMed ID: 30634629
[TBL] [Abstract][Full Text] [Related]
20. ERCC6L is a biomarker and therapeutic target for non-small cell lung adenocarcinoma.
Hou G; Lu Z; Bi Y; Deng J; Yang X
Med Oncol; 2022 Feb; 39(5):51. PubMed ID: 35150321
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]